| Boezemfibrilleren |
| | ESC Guidelines 2010 |
|
| ESC Guidelines 2010 |
| | CHADS2 versus CHA2DS2-VASc |
|
| CHADS2: Onduidelijkheid over ‘intermediate risk’ |
| | CHA2DS2-VASc |
|
| CHA2DS2-VASc |
| | Stroke Risk in AF patients |
|
| Vitamine-K antagonisten |
| | Dabigatran, Rivaroxaban, Apixaban, Endoxaban voor trombo-embolische preventie bij AF |
|
| RE-LY |
| | RE-LY: Safety outcomes |
|
| ARISTOTLE: Apixaban versus Warfarine |
| | ARISTOTLE: Apixaban versus Warfarine |
|
| Appropriate AF management? |
| | ‘Rate-related’ complicaties (RACE II) |
|
| Appropriate AF management? |
| | 3 ‘key-issues’ bij acuut AF |
|
| Acute conversie: farmacologisch of elektrisch? |
| | Conversion technique |
|
| Toch Chemische Conversie? Welk antiaritmicum? |
| | Welk antiaritmicum? |
|
| Action Potential in the Atria and the Ventricles |
| | Vernakalant |
|
| AVRO trial: Rapid Conversion of AF With Vernakalant for Infusion vs Amiodarone |
| | Appropriate AF management? |
|
| Take Home messages |
|
|
| Behandeling AF door decennia heen |
| | Conclusion |
|
Deel deze pagina met collega's en vrienden: